The NEPI Antidiabetes Study (NANSY). 1: Short‐term dose–effect relations of glimepiride in subjects with impaired fasting glucose*

Lindblad, Ulf; Lindwall, K.; Sjöstrand, Å.; Ranstam, Jonas; Melander, A

doi:10.1046/j.1463-1326.2001.00166.x

Cited by 11 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This baseline report shows that retinopathy was present in 10% of subjects with IFG and that it was associated with higher blood pressure and higher BMI. A prevalence of 10% is similar to that previously found in subjects with IGT (11%) [10]. In the Hoorn Study, the prevalence of retinopathy in individuals with normal glucose levels was 7.3% [21] and it correlated with BMI, hypertension and HbA1c.…”

Section: Discussionsupporting

confidence: 84%

“…NEPI Antidiabetes Study (NANSY) is a randomized, double‐blind and placebo‐controlled prospective trial investigating if intervention with sulphonylurea (glimipiride) in subjects with IFG will delay the conversion to type 2 diabetes [10]. NANSY‐Eye is a subprotocol studying if sulphonylurea delays the development of retinopathy in these subjects.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Retinopathy in subjects with impaired fasting glucose: the NANSY‐Eye baseline report

Tyrberg

Melander

Lövestam-Adrian

et al. 2008

Diabetes Obesity Metabolism

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Methodsmentioning

confidence: 99%

Retinopathy in subjects with impaired fasting glucose: the NANSY‐Eye baseline report

Tyrberg

Melander

Lövestam-Adrian

et al. 2008

Diabetes Obesity Metabolism

Self Cite

View full text Add to dashboard Cite

show abstract

“…in patients with impaired glucose tolerance or in obese patients with dyslipidemia prior to diabetes onset. First results might arise from two ongoing studies [190,191] investigating whether patients with impaired fasting glucose concentrations receiving a sulfonylurea or a glinide show delayed progression to diabetes.…”

Section: Strategies Targeting Ros or Rns Formation In Beta-cells Cumentioning

confidence: 99%

Oxidative stress and beta-cell dysfunction

Drews

Koehler

Düfer

2010

Pflugers Arch - Eur J Physiol

265

214

View full text Add to dashboard Cite

Diabetes mellitus type 1 and 2 (T1DM and T2DM) are complex multifactorial diseases. Loss of beta-cell function caused by reduced secretory capacity and enhanced apoptosis is a key event in the pathogenesis of both diabetes types. Oxidative stress induced by reactive oxygen and nitrogen species is critically involved in the impairment of beta-cell function during the development of diabetes. Because of their low antioxidant capacity, beta-cells are extremely sensitive towards oxidative stress. In beta-cells, important targets for an oxidant insult are cell metabolism and K(ATP) channels. The oxidant-evoked alterations of K(ATP) channel activity seem to be critical for oxidant-induced dysfunction because genetic ablation of K(ATP) channels attenuates the effects of oxidative stress on beta-cell function. Besides the effects on metabolism, interference of oxidants with mitochondria induces key events in apoptosis. Consequently, increasing antioxidant defence is a promising strategy to delay beta cell failure in (pre)-diabetic patients or during islet transplantation. Knock-out of K(ATP) channels has beneficial effects on oxidant-induced inhibition of insulin secretion and cell death. Interestingly, these effects can be mimicked by sulfonylureas that have been used in the treatment of T2DM for many years. Loss of functional K(ATP) channels leads to up-regulation of antioxidant enzymes, a process that depends on cytosolic Ca(2+). These observations are of great importance for clinical intervention because they show a possibility to protect beta-cells at an early stage before dramatic changes of the secretory capacity and loss of cell mass become manifest and lead to glucose intolerance or even overt diabetes.

show abstract

“…A number of currently ongoing studies should provide more definitive evidence (Table 3) (47,(51)(52)(53)(54)(55)(56). Short-acting insulin secretagogues, renin-angiotensin inhibitors, newer thiazolidinediones, and insulin glargine are among the drug classes being investigated.…”

Section: Estrogenmentioning

confidence: 99%

A Systematic Review of Drug Therapy to Delay or Prevent Type 2 Diabetes

Padwal

Majumdar²,

Johnson³

et al. 2005

Diabetes Care

140

View full text Add to dashboard Cite

OBJECTIVE -To systematically review the evidence for the prevention of type 2 diabetes by pharmacological therapies.RESEARCH DESIGN AND METHODS -Randomized controlled trials and cohort studies examining the effect of oral hypoglycemic agents, antiobesity agents, antihypertensive agents, statins, fibrates, and estrogen on the incidence of type 2 diabetes were identified from MEDLINE, EMBASE, the Cochrane Controlled Trials Registry, and searches of reference lists. Two reviewers independently assessed studies for inclusion and performed data extraction.RESULTS -Ten studies of oral hypoglycemic agents and 15 studies of nonoral hypoglycemic agents were found. Oral hypoglycemic agents and orlistat are the only drugs that have been studied in randomized controlled trials with diabetes incidence as the primary end point. In the largest studies of 2.5-4.0 years' duration, metformin (relative risk [RR] 0.69, 95% CI 0.57-0.83), acarbose (0.75, 0.63-0.90), troglitazone (0.45, 0.25-0.83), and orlistat (hazard ratio [HR] 0.63, 95% CI 0.46 -0.86) have all been shown to decrease diabetes incidence compared with placebo; however, follow-up rates varied from 43 to 96%. Current evidence for statins, fibrates, antihypertensive agents, and estrogen is inconclusive. In addition, the critical question of whether drugs are preventing, or simply delaying, onset of diabetes remains unresolved.CONCLUSIONS -Currently, no single agent can be definitively recommended for diabetes prevention. Future studies should be designed with diabetes incidence as the primary outcome and should be of sufficient duration to differentiate between genuine diabetes prevention as opposed to simple delay or masking of this condition. Diabetes Care 28:736 -744, 2005

show abstract

The NEPI Antidiabetes Study (NANSY). 1: Short‐term dose–effect relations of glimepiride in subjects with impaired fasting glucose*

Cited by 11 publications

References 20 publications

Retinopathy in subjects with impaired fasting glucose: the NANSY‐Eye baseline report

Retinopathy in subjects with impaired fasting glucose: the NANSY‐Eye baseline report

Oxidative stress and beta-cell dysfunction

A Systematic Review of Drug Therapy to Delay or Prevent Type 2 Diabetes

Contact Info

Product

Resources

About